Background Pancreatic ductal adenocarcinoma (PDAC) remains a significant worldwide
health problem with a poor prognosis. A borderline resectable pancreatic ductal …

Borderline resectable pancreatic adenocarcinoma (PDAC) presents challenges in definition
and treatment. Many different definitions exist for this disease. Some are based on anatomy …

Surgery followed by adjuvant chemotherapy remains the only treatment option for pancreatic
ductal adenocarcinoma (PDAC) with the chance of long-term survival. If a radical tumor …

Pancreatic cancer is a dismal disease with an increasing incidence. Despite the majority of
patients are not candidates for curative surgery, a subgroup of patients classified as …

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive tumors, with
a low rate of survival, likely due to the tendency of the tumor for early local and distant …

Borderline resectable (BR) pancreatic ductal adenocarcinoma (PDAC) is currently a well-
recognized entity, characterized by some specific anatomic, biological and conditional …

Background Neoadjuvant treatment (NT) has become standard in the management of
borderline resectable pancreatic cancer (BR-PDAC), improving prognosis. The primary …

The use of neoadjuvant chemotherapy or radiation for borderline resectable pancreatic
adenocarcinoma (BL‐PDAC) is increasing. However, the impact of neoadjuvant …

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest malignancies in the
United States. Improvements in imaging have permitted the categorization of patients …

Simple Summary Treatment of pancreatic cancer with chemotherapy followed by
chemoradiotherapy prior to surgery in patients where the tumour is in contact with major …